AUDRA MARCUM: Open Payments
NPI 1497703987 · LEXINGTON, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,154 in 167 payments from 26 companies in 2025. Trend: 2023 $3,276 · 2024 $2,733 · 2025 $3,154
Food & beverage: $3,137Education: $17
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 48 | $688 |
| Amgen Inc. | 19 | $296 |
| GENZYME CORPORATION | 13 | $294 |
| Insmed, Inc. | 14 | $223 |
| Verona Pharma, Inc. | 10 | $219 |
| Viatris Specialty LLC | 9 | $193 |
| AstraZeneca Pharmaceuticals LP | 4 | $175 |
| Grifols USA, LLC | 9 | $171 |
| CSL Behring | 4 | $109 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $96 |
Products named: NUCALA, DUPIXENT, TRELEGY ELLIPTA, TEZSPIRE, Ohtuvayre, Arikayce, YUPELRI, Prolastin-C Liquid.
Industry payments across KY — which companies pay providers there.
